Compare TOL & HOLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TOL | HOLX |
|---|---|---|
| Founded | 1967 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Medical Electronics |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.7B | 16.6B |
| IPO Year | 1994 | 1995 |
| Metric | TOL | HOLX |
|---|---|---|
| Price | $153.46 | $75.66 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 16 | 13 |
| Target Price | ★ $163.44 | $77.89 |
| AVG Volume (30 Days) | 1.2M | ★ 2.1M |
| Earning Date | 05-19-2026 | 01-01-0001 |
| Dividend Yield | ★ 0.65% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.19 | 0.79 |
| Revenue | ★ $7,143,258,000.00 | $4,100,500,000.00 |
| Revenue This Year | N/A | $4.74 |
| Revenue Next Year | $7.86 | $5.03 |
| P/E Ratio | ★ $70.36 | $95.53 |
| Revenue Growth | N/A | ★ 1.74 |
| 52 Week Low | $86.67 | $51.90 |
| 52 Week High | $168.36 | $75.49 |
| Indicator | TOL | HOLX |
|---|---|---|
| Relative Strength Index (RSI) | 47.14 | 67.03 |
| Support Level | $133.98 | $74.53 |
| Resistance Level | $168.36 | N/A |
| Average True Range (ATR) | 4.97 | 0.22 |
| MACD | -1.43 | 0.03 |
| Stochastic Oscillator | 23.99 | 96.73 |
Toll Brothers Inc is the luxury homebuilder in the USA, operating in over 60 markets across 24 states. The Fort Washington, Pennsylvania-headquartered homebuilder caters to affluent first-time, move-up, active-adult, and second-homebuyers. Toll Brothers has shifted in recent years to a greater mix of speculative, or "quick move-in" homes. The homebuilder has also expanded its price points, with a greater emphasis on "affordable luxury. Traditional homebuilding accounts for the majority of Toll Brothers' earnings, but the firm also offers ancillary mortgage, title, insurance, and other services.
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.